Paolo Tarantino, Advanced Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“Will ADCs improve outcomes for early breast cancer?
Sara Tolaney reviews ongoing trials and controversies for ADCs in eBC, highlighting the need for careful patient selection (stage, biology, quantitative target expression), sequencing strategies and attention to toxicities.”
More posts featuring Paolo Tarantino.
